DK0810829T3 - Aminosyresammensætninger og anvendelse deraf til klinisk ernæring - Google Patents

Aminosyresammensætninger og anvendelse deraf til klinisk ernæring

Info

Publication number
DK0810829T3
DK0810829T3 DK96904849T DK96904849T DK0810829T3 DK 0810829 T3 DK0810829 T3 DK 0810829T3 DK 96904849 T DK96904849 T DK 96904849T DK 96904849 T DK96904849 T DK 96904849T DK 0810829 T3 DK0810829 T3 DK 0810829T3
Authority
DK
Denmark
Prior art keywords
tnf
amino acid
diminution
levels
acid compositions
Prior art date
Application number
DK96904849T
Other languages
Danish (da)
English (en)
Inventor
Heinz Schneider
Thurman G Ronald
Original Assignee
Novartis Nutrition Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08392694 external-priority patent/US5656608B1/en
Priority claimed from GBGB9512100.0A external-priority patent/GB9512100D0/en
Application filed by Novartis Nutrition Ag filed Critical Novartis Nutrition Ag
Application granted granted Critical
Publication of DK0810829T3 publication Critical patent/DK0810829T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/13—Nucleic acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pediatric Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DK96904849T 1995-02-23 1996-02-22 Aminosyresammensætninger og anvendelse deraf til klinisk ernæring DK0810829T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08392694 US5656608B1 (en) 1995-02-23 1995-02-23 Amino acid compositions and methods of treatment using same
GBGB9512100.0A GB9512100D0 (en) 1995-06-14 1995-06-14 Improvements in or relating to organic compounds
PCT/EP1996/000739 WO1996025861A1 (en) 1995-02-23 1996-02-22 Amino acid compositions and use thereof in clinical nutrition

Publications (1)

Publication Number Publication Date
DK0810829T3 true DK0810829T3 (da) 2000-08-28

Family

ID=26307213

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96904849T DK0810829T3 (da) 1995-02-23 1996-02-22 Aminosyresammensætninger og anvendelse deraf til klinisk ernæring

Country Status (18)

Country Link
EP (1) EP0810829B1 (zh)
JP (1) JPH11501301A (zh)
KR (1) KR19980702436A (zh)
CN (1) CN1175887A (zh)
AT (1) ATE191615T1 (zh)
AU (1) AU710527B2 (zh)
BR (1) BR9607336A (zh)
CA (1) CA2210499A1 (zh)
CZ (1) CZ266797A3 (zh)
DE (1) DE69607750T2 (zh)
DK (1) DK0810829T3 (zh)
ES (1) ES2145997T3 (zh)
FI (1) FI972744A (zh)
HU (1) HUP9800049A3 (zh)
NO (1) NO973884L (zh)
PL (1) PL182205B1 (zh)
PT (1) PT810829E (zh)
WO (1) WO1996025861A1 (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512100D0 (en) * 1995-06-14 1995-08-09 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
CA2260886A1 (en) * 1996-07-30 1998-02-05 Novartis Nutrition Ag Amino acid composition and use thereof in treating tumor growth and metastasis
US6096785A (en) * 1996-07-30 2000-08-01 Novartis Nutrition Ag Amino acid compositions and use thereof in treating renal dysfunction
GB9701674D0 (en) * 1997-01-28 1997-03-19 Novartis Nutrition Ag Use of organic compounds
ATE266395T1 (de) * 1997-06-05 2004-05-15 Novartis Nutrition Ag Glycin zur vorbeugung oder behandlung von transplantatabstossungen
WO1999004781A1 (fr) * 1997-07-28 1999-02-04 The Institute Of Physical And Chemical Research Agent promoteur de protection et de survie des cellules du systeme nerveux central
US6143786A (en) * 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CN1547486A (zh) 2001-06-26 2004-11-17 抗opgl抗体
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
DE10257360A1 (de) * 2002-12-09 2004-07-08 Fresenius Kabi Deutschland Gmbh Gastro-intestinal verabreichbare Formulierung und deren Verwendung
US20060280776A1 (en) 2003-09-02 2006-12-14 Masafumi Koide Diet food
EP1591118A1 (en) 2004-04-27 2005-11-02 Nutri-Fit GmbH & Co. KG Use of melatonin in preventing postoperative complications
KR100555904B1 (ko) * 2004-05-19 2006-03-03 주식회사 오스코텍 큰느타리버섯과 오가피의 혼합 생약재 추출물 및 이를유효성분으로 하는 골다공증 예방 및 치료용 조성물
EP2032170B1 (en) * 2006-06-14 2012-11-28 N.V. Nutricia Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof
CA2709660C (en) 2008-01-04 2018-06-05 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
AU2010258888B2 (en) * 2009-06-08 2014-08-07 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
KR101213825B1 (ko) * 2010-07-16 2012-12-18 서울대학교산학협력단 세린을 유효성분으로 함유하는 지방간 질환의 예방 및 치료용 조성물
JP6000253B2 (ja) 2010-09-24 2016-09-28 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 胃腸機能を改善するための材料および方法
MX361647B (es) 2013-03-11 2018-12-13 Univ Florida Materiales y métodos para mejorar la función pulmonar y para la prevención y/o tratamiento de complicaciones pulmonares inducidas por radiación.
US20170326088A1 (en) 2014-11-24 2017-11-16 Entrinsic Health Solutions, Llc Amino acid compositions for the treatment of symptoms of disease
CN108348493B (zh) * 2015-10-02 2022-03-29 荷兰纽迪希亚公司 甘氨酸用于过敏性患者的耐受性诱导
FR3041882B1 (fr) * 2015-10-06 2019-04-12 Universite D'angers Preparation pharmaceutique pour le traitement preventif de lesions d'ischenie reperfusion
BR112019006742A2 (pt) 2016-10-04 2019-09-03 Entrinsic Health Solutions Inc composições de aminoácido e usos das mesmas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2591893B1 (fr) * 1985-12-19 1988-11-10 Centre Nat Rech Scient Compositions nutritionnelles carencees en methionine destinees a inhiber le developpement et la dissemination des tumeurs malignes chez les mammiferes
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
WO1993005780A1 (en) * 1991-09-27 1993-04-01 Board Of Regents, The University Of Texas System Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease

Also Published As

Publication number Publication date
EP0810829B1 (en) 2000-04-12
CA2210499A1 (en) 1996-08-29
CZ266797A3 (cs) 1998-03-18
ES2145997T3 (es) 2000-07-16
PL182205B1 (pl) 2001-11-30
NO973884D0 (no) 1997-08-22
NO973884L (no) 1997-10-17
PT810829E (pt) 2000-08-31
PL321238A1 (en) 1997-11-24
DE69607750D1 (de) 2000-05-18
HUP9800049A2 (hu) 1998-05-28
ATE191615T1 (de) 2000-04-15
WO1996025861A1 (en) 1996-08-29
BR9607336A (pt) 1997-11-25
HUP9800049A3 (en) 1999-01-28
EP0810829A1 (en) 1997-12-10
JPH11501301A (ja) 1999-02-02
DE69607750T2 (de) 2000-08-31
MX9706140A (es) 1997-11-29
AU4879596A (en) 1996-09-11
KR19980702436A (ko) 1998-07-15
CN1175887A (zh) 1998-03-11
FI972744A0 (fi) 1997-06-25
AU710527B2 (en) 1999-09-23
FI972744A (fi) 1997-08-22

Similar Documents

Publication Publication Date Title
DK0810829T3 (da) Aminosyresammensætninger og anvendelse deraf til klinisk ernæring
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
CA2229279A1 (en) Nutritional and/or dietary composition and method of using the same
TR199701071T2 (xx) Aktif madde ulaştırmaya mahsus bileşikler ve terkipler.
DE69427650T2 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
BR9604803A (pt) Composição farmacêutica para administração oral
GB9806632D0 (en) Peptide factor
WO2006023665A3 (en) Il-1 antagonist formulations
NO20006352L (no) Anvendelse av diazepiner til fremstilling av medisiner for behandling av patologiske tilstander eller sykdommer som involverer en av veksthormon-frigjöringsinhiberingsfaktor- reseptorene
EP0797999A3 (en) Formulations of obesity protein
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
HK1030160A1 (en) Methods of enhancing functioning of the upper gastrointestinal tract
MXPA02012064A (es) Complejos de farmaco macromoleculares y composiciones que los contienen.
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
Wildburger et al. Comparison of the values of basic fibroblast growth factor determined by an immunoassay in the sera of patients with traumatic brain injury and enhanced osteogenesis and the effects of the same sera on the fibroblast growth in vitro
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
NZ336043A (en) Use of COMT inhibitors for preventing diabetic vascular dysfunctions or neuropathy
KR102101339B1 (ko) 피부질환 예방 또는 치료용 조성물 및 제조방법
Jansen et al. Serum gastrin responses to bombesin and food in patients with hypergastrinemia
EP0905234A3 (en) Allelic variant of human STAT3
DK521389D0 (da) Praeparat til behandling af adrenoleukodystrofi
Wang et al. Effects of arginine-devoid diets in chronically uremic rats
WO2004032863A3 (en) Oral formulations for proteins and polypeptides
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta